Journal Browser

Journal Browser

Nanoparticles as New Antivirals

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Materials Science".

Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 1343

Special Issue Editor

E-Mail Website
Guest Editor
Laboratory of Nanobiology and Biomaterials, Military Institute of Hygiene and Epidemiology, Kozielska 4 St., 01-063 Warsaw, Poland
Interests: nanomaterials; antivirals; pathogenesis of herpesviral infections; cell death in virus infection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanomaterials are a diverse class of small-scale (<100 nm) objects, formed by molecular-level engineering and designed to offer unique physical and chemical properties. Recently, much effort has been devoted to the development of biomedical applications of nanoparticles. The use of nanoparticle-based antiviral agents has several advantages. Nanoparticles have the characteristics of high surface-to-volume ratios, enabling the packaging of multiple antiviral agents onto the surface of nanoparticles. This type of approach provides the possibility of targeting specific biological sites actively or passively by means of controlling hydrophobicity/lipophilicity, or modification of nanocarrier surfaces with desired compounds. A diverse portfolio of nanocarriers of various sizes, compositions, and physical parameters has now been developed. Furthermore, nanocarriers also provide an opportunity to design vaccines that can mediate targeted delivery of various antigens and adjuvants or immune regulatory agents in ways unachievable with classical vaccination approaches.

I would like to take this opportunity to invite you to submit your manuscript to the Special Issue on “Nanoparticles as New Antivirals” in IJMS, which will surely act as an excellent vehicle for the dissemination of your research. We will accept reviews and original scientific papers in this Special Issue and look forward to your valuable contribution.

Dr. Malgorzata Krzyzowska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • nanomaterials
  • nanoparticles
  • DNA/RNA viruses
  • pharmaceuticals
  • nanocarriers
  • nanoadjuvants
  • vaccines
  • antivirals

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


19 pages, 6645 KiB  
Folate-Targeted Nanocarriers Co-Deliver Ganciclovir and miR-34a-5p for Combined Anti-KSHV Therapy
by Fangling Li, Dongdong Cao, Wenyi Gu, Dongmei Li, Zhiyong Liu and Lin Cui
Int. J. Mol. Sci. 2024, 25(5), 2932; https://doi.org/10.3390/ijms25052932 - 2 Mar 2024
Viewed by 684
Kaposi’s sarcoma-associated herpesvirus (KSHV) can cause a variety of malignancies. Ganciclovir (GCV) is one of the most efficient drugs against KSHV, but its non-specificity can cause other side effects in patients. Nucleic acid miR-34a-5p can inhibit the transcription of KSHV RNA and has [...] Read more.
Kaposi’s sarcoma-associated herpesvirus (KSHV) can cause a variety of malignancies. Ganciclovir (GCV) is one of the most efficient drugs against KSHV, but its non-specificity can cause other side effects in patients. Nucleic acid miR-34a-5p can inhibit the transcription of KSHV RNA and has great potential in anti-KSHV therapy, but there are still problems such as easy degradation and low delivery efficiency. Here, we constructed a co-loaded dual-drug nanocomplex (GCV@ZIF-8/PEI-FA+miR-34a-5p) that contains GCV internally and adsorbs miR-34a-5p externally. The folic acid (FA)-coupled polyethyleneimine (PEI) coating layer (PEI-FA) was shown to increase the cellular uptake of the nanocomplex, which is conducive to the enrichment of drugs at the KSHV infection site. GCV and miR-34a-5p are released at the site of the KSHV infection through the acid hydrolysis characteristics of ZIF-8 and the “proton sponge effect” of PEI. The co-loaded dual-drug nanocomplex not only inhibits the proliferation and migration of KSHV-positive cells but also decreases the mRNA expression level of KSHV lytic and latent genes. In conclusion, this co-loaded dual-drug nanocomplex may provide an attractive strategy for antiviral drug delivery and anti-KSHV therapy. Full article
(This article belongs to the Special Issue Nanoparticles as New Antivirals)
Show Figures

Graphical abstract

Back to TopTop